Life Sciences Tools and Services
Company Overview of NuGEN Technologies, Inc.
NuGEN Technologies, Inc. develops and commercializes technologies and products for accurate and targeted genomic analysis. The company offers DNA and RNA sample preparation products for use in research and diagnostic applications. It provides a portfolio of technologies to address microarray and Next-Gen Sequencing applications, including RNA-Seq, targeted resequencing of DNA and RNA, target capture, ChIP-Seq, and Methyl-Seq; sample preparation solutions for RNA and DNA that enable the analysis of specimens, which are limited or of poor quality on microarray and qPCR analysis platforms; and sample preparation solutions for high throughput applications, such as Next Gen Sequencing, microarray...
201 Industrial Road
San Carlos, CA 94070
Founded in 2000
Key Executives for NuGEN Technologies, Inc.
Senior Director of Product Marketing
Director of Technical Support
Director of Sales - Asia Pacific
Compensation as of Fiscal Year 2016.
NuGEN Technologies, Inc. Key Developments
NuGEN Technologies, Inc. Announces Launch of Fusion Data Analysis Application, Enabling Simplified Fusion Detection and Discovery
Aug 2 16
NuGEN Technologies, Inc. announced the availability of the Ovation Fusion Detection application, providing a data analysis tool for the Ovation Fusion Target Enrichment System V2 that enables a complete sample-to-analysis workflow for fusion discovery and detection. The Ovation Fusion Panel Target Enrichment System V2 allows the comprehensive interrogation of multiple, specific genes for RNA sequencing, significantly simplifying fusion detection when compared with standard RNA sequencing approaches. Sequence data generated from this targeted enrichment technology can then be analyzed using the application on the BaseSpace cloud or as a local Linux installation. Structural chromosome rearrangements resulting in fusion genes are implicated in all types of human cancer, making the discovery and detection of these fusions valuable for both diagnostic and prognostic purposes. NuGEN’s products offer rapid and simple workflows for a broad range of next generation DNA and RNA sequencing applications, enabling highly sensitive detection of variants and expression levels from tissues, single cells and liquid biopsies. NuGEN’s products are used by thousands of scientists worldwide and have been cited in over 2,000 peer-reviewed publications.
NuGEN Technologies, Inc. Announces Management Changes
Jun 14 16
NuGEN Technologies, Inc. announced the appointment of Nitin Sood as Chief Executive Officer. He succeeds Elizabeth Hutt who recently left to pursue another opportunity. Mr. Sood comes to NuGEN from PerkinElmer, where he served as Vice President and General Manager of their life science instruments business spanning a portfolio of products in imaging, detection, tissue pathology, automation and NGS sample prep. Prior to his current role, Mr. Sood was the Chief Executive Officer of Boreal Genomics.
NuGEN Technologies, Inc. Announces Commercial Introduction of Ovation SoLo RNA-Seq System
Feb 20 16
NuGEN Technologies, Inc. announced the launch of the Ovation SoLo RNA-Seq System, the company’s latest tool in its suite of sample preparation products supporting research in areas previously hampered by sample input limitations such as single cells and liquid biopsy. The Ovation SoLo kit will facilitate research in areas such as blood-borne biomarkers, cellular heterogeneity, and the study of single cell transcriptomics. Ovation SoLo provides a complete end-to-end solution for whole transcriptome analyses starting directly from cells or isolated RNA. The result is the most comprehensive cellular data and the best biology from the broadest range of input levels in samples with limited RNA quantity including single cell, liquid biopsy, and other low input RNA samples. The system features an improved method for ribosomal depletion of > 90%, efficient cDNA generation from ultra-low inputs that provides a complete representation of the entire transcriptome, and the capability to unambiguously identify PCR duplicates.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|